Compare GMM & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GMM | XLO |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 41.8M |
| IPO Year | 2023 | 2021 |
| Metric | GMM | XLO |
|---|---|---|
| Price | $1.38 | $0.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 40.6K | ★ 419.8K |
| Earning Date | 08-18-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $48,171,048.00 | $31,804,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | $0.81 | ★ N/A |
| Revenue Growth | 41.74 | ★ 588.40 |
| 52 Week Low | $0.94 | $0.62 |
| 52 Week High | $4.75 | $1.70 |
| Indicator | GMM | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 60.50 |
| Support Level | $0.94 | $0.63 |
| Resistance Level | $1.54 | $0.68 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 75.78 | 87.72 |
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.